CD274 and non-small cell lung carcinoma: Our results are consistent with those of previous trials in which monotherapy with other PD-1 and PD-L1 inhibitors has shown benefit in patients with advanced NSCLC with and without brain metastases,18,19 lending further support of a role for immunotherapy in these patients.